Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-12-26
2006-12-26
Afremova, Vera (Department: 1651)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S009100, C424S236100
Reexamination Certificate
active
07153514
ABSTRACT:
The present invention relates to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
REFERENCES:
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5837265 (1998-11-01), Montal et al.
patent: 6365164 (2002-04-01), Schmidt
patent: WO 99/03483 (1999-01-01), None
Boyd et al. Lancet. Aug. 1996. vol. 348, pp. 481-482.
Beleggia et al., Arch. It. Urol., LXIX, (S.1): 61-63, 1997 (English Abstract).
Fowler et al., British J of Urol., Oct. 22, 1991, 387-389.
Nanninga, John B., Oxins (1993) p. 589-590.
Bruschini et al., “Neurologic Control of Prostatic Secretion in the Dog”;Invest. Urol.,15(4):288-290 (Jan. 1978).
Downie et al., “Evidence for a Spinal Site of Action of Clonidine on Somatic and Viscerosomatic Reflex Activity Evoked on the Pudendal Nerve in Cats”;J. Pharmacol. Exp. Ther.,246(1):352-358 (May 1988).
Dykstra et al., “Treatment of Detrusor-Sphincter Dyssynergia with Botulinum A Toxin: A Double-Blind Study”;Arch. Phys. Med. Rehabil.,71:24-26 (Jan. 1990).
Håkanson et al., “Multiple Tachykinin Pools in Sensory Nerve Fibres in the Rabbit Iris”;Neuroscience,21(3):943-950 (1987).
Higgins et al., “Studies on the Structure and Intrinsic Innervation of the Normal Human Prostate”;Prostate Suppl.,2:5-16 (1989).
Ishizuka et al., “Urodynamic Effects of Intravesical Resiniferatoxin and Capsalcin in Conscious Rats With and Without Outflow Obstruction”;J. Urology,154:611-616 (Aug. 1995).
Joo et al., “Initial North American Experience with Botulinum Toxin Type A for Treatmetn of Anismus”;Dis. Colon. Rectum,39(10):1107-1111 (Oct. 1996).
Lepor “Role of Long-Acting Selective Alpha-1 Blockers in the Treatment of Benign Prostatic Hyperplasia”;Urol. Clin. North Am.,17(3):651-658 (Aug. 1990).
Maggi et al., “Cystometric Evidence That Capsalcin-Sensitive Nerves Modulate the Afferent Branch of Micturition Reflex in Humans”;J. Urol.,142:150-154 (Jul. 1989).
Mocchetti, “Pharmacology of Neuronal Gene Expression”;Pharmacol. Res.,21(Suppl. 2):85-95 (1989).
Schurch et al.,J. Urol.,155:1023-1029 (1996).
Tim et al.,Botulinum Toxin Therapy,9(6):327-332 (1992).
Afremova Vera
Sheridan Ross PC
The Regents of the University of Colorado
LandOfFree
Use of botulinum toxin therapy for prostatic hyperplasia and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of botulinum toxin therapy for prostatic hyperplasia and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of botulinum toxin therapy for prostatic hyperplasia and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3718425